Franklin Resources Inc. increased its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 177.8% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 263,748 shares of the biotechnology company's stock after purchasing an additional 168,790 shares during the quarter. Franklin Resources Inc. owned approximately 0.13% of BioCryst Pharmaceuticals worth $1,968,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Signaturefd LLC lifted its stake in BioCryst Pharmaceuticals by 560.5% in the 2nd quarter. Signaturefd LLC now owns 6,598 shares of the biotechnology company's stock worth $41,000 after acquiring an additional 5,599 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of BioCryst Pharmaceuticals by 21.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,483 shares of the biotechnology company's stock worth $57,000 after purchasing an additional 1,322 shares in the last quarter. nVerses Capital LLC acquired a new stake in shares of BioCryst Pharmaceuticals during the second quarter worth approximately $63,000. DRW Securities LLC acquired a new position in BioCryst Pharmaceuticals in the 2nd quarter valued at approximately $74,000. Finally, Xponance Inc. increased its stake in BioCryst Pharmaceuticals by 13.1% in the 2nd quarter. Xponance Inc. now owns 12,980 shares of the biotechnology company's stock valued at $80,000 after buying an additional 1,505 shares during the period. Institutional investors and hedge funds own 85.88% of the company's stock.
Wall Street Analysts Forecast Growth
A number of equities research analysts have issued reports on BCRX shares. Barclays lifted their target price on shares of BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the company an "equal weight" rating in a research note on Tuesday, November 5th. Needham & Company LLC restated a "buy" rating and issued a $14.00 target price on shares of BioCryst Pharmaceuticals in a research note on Tuesday, November 5th. Finally, Royal Bank of Canada reaffirmed an "outperform" rating and issued a $10.00 target price on shares of BioCryst Pharmaceuticals in a research report on Tuesday, November 5th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, BioCryst Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus price target of $15.60.
Read Our Latest Report on BCRX
BioCryst Pharmaceuticals Stock Down 0.1 %
Shares of NASDAQ:BCRX traded down $0.01 on Friday, reaching $7.71. The company had a trading volume of 998,002 shares, compared to its average volume of 2,823,892. The stock has a 50-day moving average price of $7.64 and a 200 day moving average price of $7.45. BioCryst Pharmaceuticals, Inc. has a twelve month low of $4.03 and a twelve month high of $8.88. The stock has a market capitalization of $1.60 billion, a P/E ratio of -12.64 and a beta of 1.79.
BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last announced its quarterly earnings results on Monday, November 4th. The biotechnology company reported ($0.07) EPS for the quarter, meeting the consensus estimate of ($0.07). The company had revenue of $117.10 million for the quarter, compared to analyst estimates of $113.99 million. During the same quarter last year, the business earned ($0.19) EPS. The company's revenue for the quarter was up 35.1% on a year-over-year basis. On average, sell-side analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.38 earnings per share for the current fiscal year.
About BioCryst Pharmaceuticals
(
Free Report)
BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.
See Also
Before you consider BioCryst Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioCryst Pharmaceuticals wasn't on the list.
While BioCryst Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
